TIRZEPATIDE REDUCES ALBUMINURIA IN PATIENTS WITH TYPE 2 DIABETES: POST HOC POOLED ANALYSIS OF SURPASS-1 to -5

R. J. Wiese,H. J. L. Heerspink,K. R. Tuttle,I. Pavo,A. Haupt, Z. Yang,A. Hemmingway,D. Z. I. Cherney,N. Sattar

Canadian journal of diabetes（2023）

Cited 0|Views1

No score

Abstract

A post hoc analysis of the SURPASS-4 trial suggested that the glucose-dependent insulinotropic polypeptide/ glucagon-like peptide-1 (GIP/GLP-1) receptor agonist tirzepatide (TZP) could have a potential kidney protective effect in people with T2D and high cardiovascular risk by slowing the rate of estimated glomerular filtration rate (eGFR) decline and reducing urine albumin-creatinine ratio (UACR) vs insulin glargine over 2 years. In the current post hoc analysis, we explored effects of TZP on UACR changes in SURPASS-1 to -5 trials.

Translated text

Key words

Type 2 Diabetes

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined